Delving into the Latest Updates on LTN Pharmaceuticals, Inc. with Synapse

ARMOR3-SV: A Phase 3, Randomized, Open Label, Multi-Center, Controlled Study of Galeterone Compared to Enzalutamide in Men Expressing Androgen Receptor Splice Variant-7 mRNA (AR-V7) Metastatic (M1) Castrate Resistant Prostate Cancer (CRPC)

The purpose of this study is to compare galeterone to enzalutamide in men expressing androgen receptor spice variant-7 mRNA (AR-V7) in metastatic (M1) castrate resistant prostate cancer (CRPC).

开始日期2015-06-01

申办/合作机构

LTN Pharmaceuticals, Inc.

NCT01709734 / Terminated临床2期

ARMOR2: A 2 Part, Phase 2 Trial of Galeterone in the Treatment of Castration Resistant Prostate Cancer

A Phase 2, 2 part trial to evaluate the safety and efficacy of galeterone in castration resistant prostate cancer (CRPC) patients.

开始日期2012-12-01

申办/合作机构

LTN Pharmaceuticals, Inc.

NCT00959959 / Completed临床1期

ARMOR1: Phase 1, Open Label, Dose Escalation Trial of TOK-001 for the Treatment of Chemotherapy Naive Castration Resistant Prostate Cancer

The purpose of this study is to determine whether TOK-001 is safe and shows biological effect in the treatment of castration resistant prostate cancer (CRPC).

开始日期2009-10-01

申办/合作机构

LTN Pharmaceuticals, Inc.

100 项与 LTN Pharmaceuticals, Inc. 相关的临床结果

登录后查看更多信息

0 项与 LTN Pharmaceuticals, Inc. 相关的专利（医药）

登录后查看更多信息

100 项与 LTN Pharmaceuticals, Inc. 相关的药物交易

登录后查看更多信息

100 项与 LTN Pharmaceuticals, Inc. 相关的转化医学

登录后查看更多信息